ライフサイエンスコーパス: inhaled steroid

1 ptom control, despite lower dose maintenance inhaled steroids.

2 duction in patients on moderate or high-dose inhaled steroids.

3 o predict success or failure of reduction of inhaled steroids.

4 ned as persisting symptoms despite high-dose inhaled steroids.

5 levels in subjects with asthma treated with inhaled steroids.

6 eversed, at least in part, by treatment with inhaled steroids.

7 sthma severity either as monotherapy or with inhaled steroids.

8 pected to be a prominent cellular target for inhaled steroids.

9 the excellent efficacy/tolerability ratio of inhaled steroids.

10 = 0.002), and filled fewer prescriptions for inhaled steroids (1.44 versus 1.74 Rx/yr, p = 0.038), wh

11 beta2-agonist, alone or in combination with inhaled steroids (2 mg or less) daily.

12 Medications included albuterol (81%), inhaled steroids (38%), cromolyn (35%), and theophylline

13 % vs. 4%; P = 0.011); and use of medication (inhaled steroids, 9% vs. 6%; P = 0.042) (antibiotics, 12

14 ded at least 70% of the prescribed number of inhaled-steroid actuations.

15 tients followed conversion to a standardized inhaled steroid and were treated with 7 injections of ei

16 fect the inverse relationship between use of inhaled steroids and hospitalization.

17 Prescription rate of inhaled steroids and patients satisfaction was higher in

18 The asthma section includes a review of inhaled steroids and their potential side effects.

19 Inhaled steroids and, to a lesser extent, cromolyn confe

20 ma self-management, measured as adherence to inhaled steroids, and asthma outcomes.

21 t as measured by maintenance of control when inhaled steroids are discontinued.

22 Recent studies confirmed that inhaled steroids are the most efficacious therapy for ch

23 These results support the use of inhaled steroids by individuals who require more than oc

24 Fluticasone, an inhaled steroid commonly used to treat asthma, produced

25 quality of life, and allowed lower doses of inhaled steroid compared with placebo.

26 ction were reviewed every 8 weeks, and their inhaled steroid dose halved if clinically indicated.

27 ng beta2-agonists may allow for reduction of inhaled steroid doses.

28 We hypothesized that withdrawal of inhaled steroids in elderly patients with severe irrever

29 Data are from the Inhaled Steroids in Obstructive Lung Disease (ISOLDE) tr

30 le to substantially reduce and even withdraw inhaled steroids in the placebo arm.

31 ation frequency and severity in COPD such as inhaled steroids, long-acting bronchodilators, and their

32 ugs used for long-term management, including inhaled steroids, long-acting inhaled beta2-stimulants,

33 ve controlled clinical trials, data from 744 inhaled steroid nonusers and 685 inhaled steroid users o

34 In inhaled steroid nonusers nocturnal symptoms classified t

35 at a better response of the small airways to inhaled steroids or montelukast associates with better a

36 ars): 31 with nonsevere asthma (treated with inhaled steroids or not) and 11 with severe asthma.

37 New high-potency inhaled steroid preparations are clearly effective in th

38 rty children with stable asthma eligible for inhaled steroid reduction were reviewed every 8 weeks, a

39 that may influence adherence to twice-daily inhaled steroid regimens.

40 , low exhaled nitric oxide levels, and lower inhaled steroid requirements.

41 ent-clinician communication for adherence to inhaled-steroid schedules.

42 Pharmacogenetics of Adrenal Suppression with Inhaled Steroid Study).

43 m patients with moderate asthma treated with inhaled steroids, suggesting relative insensitivity to i

44 Inhaled steroids, the current standard therapy, are not

45 sed therapeutic approaches include high-dose inhaled steroids, the Symbicort maintenance and reliever

46 We did a post-hoc analysis of the 3 year inhaled Steroid Treatment As Regular Therapy (START) stu

47 d nitric oxide, blood eosinophil counts, and inhaled steroid treatment did not influence cough parame

48 A weaker relationship existed between inhaled steroid use and vertebral fractures: age-adjuste

49 id use: Never Steroid Users (NSU) (n = 117), Inhaled Steroid Users (ISU) (n = 70), and Systemic Stero

50 ta from 744 inhaled steroid nonusers and 685 inhaled steroid users on asthma control were collected a

51 of hospitalization among those who received inhaled steroids was 0.5 (95% confidence interval [CI],

52 e of the 4 literature signals of exposure to inhaled steroids were confirmed (cleft palate, cleft lip

53 contrast, subjects with asthma treated with inhaled steroids were found to have greater HDAC activit

54 may allow clinicians to minimize the dose of inhaled steroids while controlling symptoms.

55 It is suggested that higher doses of inhaled steroids with long-acting beta2 agonists should